Gliatech To Submit Third-Party Audit Data To FDA In The Third Quarter
This article was originally published in The Gray Sheet
Executive Summary
Gliatech remains on schedule to submit an independent clinical study site audit report in the third quarter related to its Adcon-L gel anti-adhesion product for lumbar surgery, the firm says.
You may also be interested in...
Gliatech Weighing Adcon Sale, Bankruptcy Filing; DoJ Makes Example Of Firm
Gliatech is considering the sale of its flagship Adcon anti-adhesion technology and filing for bankruptcy following a recent settlement with the Department of Justice due to failure to supply required information to FDA
Gliatech Weighing Adcon Sale, Bankruptcy Filing; DoJ Makes Example Of Firm
Gliatech is considering the sale of its flagship Adcon anti-adhesion technology and filing for bankruptcy following a recent settlement with the Department of Justice due to failure to supply required information to FDA
Adcon Data Will Be Evaluated By Third Party In Wake Of FDA Action - Gliatech
Gliatech will contract an independent evaluator to review magnetic resonance imaging data associated with postmarket studies of the company's Adcon-L gel anti-adhesion product for lumbar surgery.